Morgan Stanley raised the firm’s price target on Exelixis (EXEL) to $45 from $44 and keeps an Overweight rating on the shares. Cabo continues to demonstrate sustained demand and the NET launch progresses well with roughly $100M expected in contribution to 2025 net product revenue, the analyst tells investors in a research note. The firm added the company expects to submit the NDA in previously treated mCRC in December 2025, pending the U.S. government re-opening.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL: